CN103251551A - 一种可注射性氧化石墨烯/石墨烯复合水凝胶及其制备方法 - Google Patents
一种可注射性氧化石墨烯/石墨烯复合水凝胶及其制备方法 Download PDFInfo
- Publication number
- CN103251551A CN103251551A CN2013101892020A CN201310189202A CN103251551A CN 103251551 A CN103251551 A CN 103251551A CN 2013101892020 A CN2013101892020 A CN 2013101892020A CN 201310189202 A CN201310189202 A CN 201310189202A CN 103251551 A CN103251551 A CN 103251551A
- Authority
- CN
- China
- Prior art keywords
- graphene
- solution
- aqueous solution
- concentration
- alpha
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 title claims abstract description 155
- 229910021389 graphene Inorganic materials 0.000 title claims abstract description 138
- 239000000017 hydrogel Substances 0.000 title claims abstract description 77
- 239000002131 composite material Substances 0.000 title claims abstract description 34
- 238000002360 preparation method Methods 0.000 title claims abstract description 28
- 239000007864 aqueous solution Substances 0.000 claims abstract description 83
- 239000003814 drug Substances 0.000 claims abstract description 78
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 78
- 239000000243 solution Substances 0.000 claims abstract description 61
- 229920001450 Alpha-Cyclodextrin Polymers 0.000 claims abstract description 48
- HFHDHCJBZVLPGP-RWMJIURBSA-N alpha-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO HFHDHCJBZVLPGP-RWMJIURBSA-N 0.000 claims abstract description 48
- 229940043377 alpha-cyclodextrin Drugs 0.000 claims abstract description 48
- 229940079593 drug Drugs 0.000 claims abstract description 36
- VSJKWCGYPAHWDS-FQEVSTJZSA-N camptothecin Chemical compound C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-FQEVSTJZSA-N 0.000 claims abstract description 20
- 229910002804 graphite Inorganic materials 0.000 claims abstract description 18
- 239000010439 graphite Substances 0.000 claims abstract description 18
- 238000002156 mixing Methods 0.000 claims abstract description 7
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims description 24
- 238000003756 stirring Methods 0.000 claims description 23
- 229920000570 polyether Polymers 0.000 claims description 16
- 238000000034 method Methods 0.000 claims description 15
- MWWSFMDVAYGXBV-RUELKSSGSA-N Doxorubicin hydrochloride Chemical compound Cl.O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 MWWSFMDVAYGXBV-RUELKSSGSA-N 0.000 claims description 8
- 229960002918 doxorubicin hydrochloride Drugs 0.000 claims description 8
- 238000001132 ultrasonic dispersion Methods 0.000 claims description 8
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 7
- 239000007788 liquid Substances 0.000 claims description 6
- 229920000858 Cyclodextrin Polymers 0.000 claims description 5
- 239000003638 chemical reducing agent Substances 0.000 claims description 5
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 claims description 5
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 4
- 238000006243 chemical reaction Methods 0.000 claims description 4
- 230000001186 cumulative effect Effects 0.000 claims description 4
- 229930182830 galactose Natural products 0.000 claims description 4
- 235000011121 sodium hydroxide Nutrition 0.000 claims description 3
- 108091003079 Bovine Serum Albumin Proteins 0.000 claims description 2
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 claims description 2
- 229930003268 Vitamin C Natural products 0.000 claims description 2
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 claims description 2
- 229940098773 bovine serum albumin Drugs 0.000 claims description 2
- 235000019154 vitamin C Nutrition 0.000 claims description 2
- 239000011718 vitamin C Substances 0.000 claims description 2
- KLWPJMFMVPTNCC-UHFFFAOYSA-N Camptothecin Natural products CCC1(O)C(=O)OCC2=C1C=C3C4Nc5ccccc5C=C4CN3C2=O KLWPJMFMVPTNCC-UHFFFAOYSA-N 0.000 abstract 2
- 229940127093 camptothecin Drugs 0.000 abstract 2
- VSJKWCGYPAHWDS-UHFFFAOYSA-N dl-camptothecin Natural products C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)C5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-UHFFFAOYSA-N 0.000 abstract 2
- 239000000499 gel Substances 0.000 description 13
- 229920001992 poloxamer 407 Polymers 0.000 description 12
- 230000003647 oxidation Effects 0.000 description 9
- 238000007254 oxidation reaction Methods 0.000 description 9
- 239000003937 drug carrier Substances 0.000 description 7
- 239000008367 deionised water Substances 0.000 description 4
- 229910021641 deionized water Inorganic materials 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 230000002209 hydrophobic effect Effects 0.000 description 4
- 238000002835 absorbance Methods 0.000 description 3
- 238000011068 loading method Methods 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- SPJOZZSIXXJYBT-UHFFFAOYSA-N Fenson Chemical compound C1=CC(Cl)=CC=C1OS(=O)(=O)C1=CC=CC=C1 SPJOZZSIXXJYBT-UHFFFAOYSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 239000012620 biological material Substances 0.000 description 2
- 229940000425 combination drug Drugs 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 230000008034 disappearance Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 238000012377 drug delivery Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 230000009969 flowable effect Effects 0.000 description 2
- -1 graphite alkene Chemical class 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 239000001117 sulphuric acid Substances 0.000 description 2
- 235000011149 sulphuric acid Nutrition 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- NWXMGUDVXFXRIG-WESIUVDSSA-N (4s,4as,5as,6s,12ar)-4-(dimethylamino)-1,6,10,11,12a-pentahydroxy-6-methyl-3,12-dioxo-4,4a,5,5a-tetrahydrotetracene-2-carboxamide Chemical compound C1=CC=C2[C@](O)(C)[C@H]3C[C@H]4[C@H](N(C)C)C(=O)C(C(N)=O)=C(O)[C@@]4(O)C(=O)C3=C(O)C2=C1O NWXMGUDVXFXRIG-WESIUVDSSA-N 0.000 description 1
- 229930195573 Amycin Natural products 0.000 description 1
- 229930012538 Paclitaxel Natural products 0.000 description 1
- 210000000476 body water Anatomy 0.000 description 1
- 239000000599 controlled substance Substances 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 239000010408 film Substances 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000004005 microsphere Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 239000002086 nanomaterial Substances 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 229960001592 paclitaxel Drugs 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 239000008177 pharmaceutical agent Substances 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000007493 shaping process Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
- 208000016261 weight loss Diseases 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
Images
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
Claims (10)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201310189202.0A CN103251551B (zh) | 2013-05-20 | 2013-05-20 | 一种可注射性氧化石墨烯/石墨烯复合水凝胶及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201310189202.0A CN103251551B (zh) | 2013-05-20 | 2013-05-20 | 一种可注射性氧化石墨烯/石墨烯复合水凝胶及其制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN103251551A true CN103251551A (zh) | 2013-08-21 |
CN103251551B CN103251551B (zh) | 2016-04-13 |
Family
ID=48955996
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201310189202.0A Expired - Fee Related CN103251551B (zh) | 2013-05-20 | 2013-05-20 | 一种可注射性氧化石墨烯/石墨烯复合水凝胶及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN103251551B (zh) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105125478A (zh) * | 2015-08-26 | 2015-12-09 | 金陵科技学院 | 一种具有pH敏感特性的可注射性的纳米复合水凝胶 |
CN107022093A (zh) * | 2017-03-18 | 2017-08-08 | 华南理工大学 | 一种环糊精氧化石墨烯双交联水凝胶及其制备方法 |
CN108083252A (zh) * | 2017-12-21 | 2018-05-29 | 上海应用技术大学 | 一种以嵌段聚合物为模板制备孔径均匀的碳材料的方法 |
CN110354072A (zh) * | 2019-09-12 | 2019-10-22 | 中国科学院兰州化学物理研究所 | 一种近红外光响应的氧化石墨烯/凹凸棒石复合超分子水凝胶的制备和应用 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102552110A (zh) * | 2010-12-09 | 2012-07-11 | 国家纳米科学中心 | 一种负载药物的水凝胶体系及其制备方法 |
-
2013
- 2013-05-20 CN CN201310189202.0A patent/CN103251551B/zh not_active Expired - Fee Related
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102552110A (zh) * | 2010-12-09 | 2012-07-11 | 国家纳米科学中心 | 一种负载药物的水凝胶体系及其制备方法 |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105125478A (zh) * | 2015-08-26 | 2015-12-09 | 金陵科技学院 | 一种具有pH敏感特性的可注射性的纳米复合水凝胶 |
CN107022093A (zh) * | 2017-03-18 | 2017-08-08 | 华南理工大学 | 一种环糊精氧化石墨烯双交联水凝胶及其制备方法 |
CN108083252A (zh) * | 2017-12-21 | 2018-05-29 | 上海应用技术大学 | 一种以嵌段聚合物为模板制备孔径均匀的碳材料的方法 |
CN110354072A (zh) * | 2019-09-12 | 2019-10-22 | 中国科学院兰州化学物理研究所 | 一种近红外光响应的氧化石墨烯/凹凸棒石复合超分子水凝胶的制备和应用 |
CN110354072B (zh) * | 2019-09-12 | 2022-07-12 | 中国科学院兰州化学物理研究所 | 一种近红外光响应的氧化石墨烯/凹凸棒石复合超分子水凝胶的制备和应用 |
Also Published As
Publication number | Publication date |
---|---|
CN103251551B (zh) | 2016-04-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Zhu et al. | Multi-functional silica-based mesoporous materials for simultaneous delivery of biologically active ions and therapeutic biomolecules | |
Peng et al. | Injectable and biodegradable thermosensitive hydrogels loaded with PHBHHx nanoparticles for the sustained and controlled release of insulin | |
Tölli et al. | In vivo biocompatibility of porous silicon biomaterials for drug delivery to the heart | |
He et al. | Charge reversal induced colloidal hydrogel acts as a multi-stimuli responsive drug delivery platform for synergistic cancer therapy | |
CN106164136B (zh) | 涉及稳定化聚合硅酸盐组合物的材料和方法 | |
CN103110957B (zh) | 一种氧化石墨烯药物载体及其制备方法和应用 | |
EP1595534A1 (en) | Gel composition comprising charged polymers | |
MXPA05009493A (es) | Composicion de insulina oral y metodos para producirla y utilizarla. | |
CN103251551B (zh) | 一种可注射性氧化石墨烯/石墨烯复合水凝胶及其制备方法 | |
CN107007875B (zh) | 一种酶与温度双响应性载药水凝胶及其制备方法与应用 | |
CN101804021A (zh) | 载多烯紫杉醇纳米粒混合胶束制剂及冻干剂的制备方法 | |
CN104306325A (zh) | 一种抗肿瘤水凝胶的制备方法 | |
Phan et al. | Ionically cross-linked alginate-chitosan core-shell hydrogel beads for oral delivery of insulin | |
Xiao et al. | A facile strategy for fine-tuning the stability and drug release of stimuli-responsive cross-linked micellar nanoparticles towards precision drug delivery | |
Mi et al. | Postsurgical wound management and prevention of triple-negative breast cancer recurrence with a pryoptosis-inducing, photopolymerizable hydrogel | |
Sarkar et al. | Mesoporous silica nanoparticles: drug delivery vehicles for antidiabetic molecules | |
CN115177580A (zh) | 一种医用载姜黄素温度敏感型水凝胶的制备方法 | |
CN101721375B (zh) | 胰岛素缓释微米球组合物及其制备方法 | |
CN105596298A (zh) | 一种包载丁丙诺啡的peg-plga缓释微球及其制备方法 | |
Yadav et al. | Modulation of physicochemical properties of polymers for effective insulin delivery systems | |
Liu et al. | Metal-organic framework-based injectable in situ gel for multi-responsive insulin delivery | |
CN1985989A (zh) | 碱性成纤维生长因子聚乳酸缓释纳米微球凝胶及其制备方法 | |
CN113995714A (zh) | 一种顺铂交联的蛋白水凝胶及制备方法 | |
Zhang et al. | Nanochaperones tailored for insulin delivery to reduce immune clearance and enhance bioavailability of insulin | |
Cui et al. | Engineering mesoporous bioactive glasses for emerging stimuli-responsive drug delivery and theranostic applications |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20220125 Address after: 510000 room 613, No. 2, Huanxi West Road, Tianhe District, Guangzhou City, Guangdong Province Patentee after: Guangzhou whale Shield Network Technology Co.,Ltd. Address before: 211169 No. 99, Hongjing Avenue, Jiangning, Nanjing, Jiangsu Patentee before: JINLING INSTITUTE OF TECHNOLOGY |
|
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20220602 Address after: 450000 No. 12, Dongqing street, high tech Development Zone, Zhengzhou City, Henan Province Patentee after: ZHENGZHOU YIPIN PHARMACEUTICAL TECHNOLOGY CO.,LTD. Address before: 510000 room 613, No. 2, Huanxi West Road, Tianhe District, Guangzhou City, Guangdong Province Patentee before: Guangzhou whale Shield Network Technology Co.,Ltd. |
|
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20160413 |